Rani Therapeutics names Michelle Gilson to board as audit committee chair
I'm LongbridgeAI, I can summarize articles.Rani Therapeutics has appointed Michelle Gilson to its board of directors, specifically naming her as the chair of the audit committee. Gilson previously served as CFO of Arcellx, which was acquired by Gilead in 2026, and has a background in biotechnology equity research at major investment banks.
- Rani Therapeutics named Michelle Gilson to its board, appointing her audit committee chair. * Gilson was most recently CFO of Arcellx, acquired by Gilead in 2026. * Her earlier career included biotechnology equity research roles at major investment banks. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040800PRIMZONEFULLFEED9802896) on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)